Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | BLM | P54132 | 2/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.80 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.80 |
| ▸ | CNR2 | P34972 | 2/20 | 0.80 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.80 |
| ▸ | FAAH | O00519 | 1/20 | 0.80 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.80 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8052707 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1MEN1BLMKMT2A | |
| SCHEMBL13767988 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1MEN1BLMKMT2A | |
| SCHEMBL30603566 | 0.94 | CNR1 (0.88) | CNR1ALDH1A1MEN1BLMKMT2A | |
| SCHEMBL886860 | 0.94 | CNR1 (0.88) | CNR1ALDH1A1MEN1BLMKMT2A | |
| SCHEMBL10609779 | 0.94 | CNR1 (0.88) | CNR1ALDH1A1MEN1BLMKMT2A | |
| SCHEMBL31030918 | 0.94 | CNR1 (0.88) | CNR1ALDH1A1MEN1BLMKMT2A | |
| SCHEMBL10600938 | 0.92 | CNR1 (0.85) | CNR1ALDH1A1MEN1BLMKMT2A | |
| SCHEMBL2193040 | 0.90 | CNR1 (1.00) | CNR1ALDH1A1MEN1BLMKMT2A | |
| SCHEMBL1228084 | 0.90 | CNR1 (1.00) | CNR1ALDH1A1MEN1BLMKMT2A | |
| SCHEMBL22301833 | 0.89 | CNR1 (0.80) | CNR1ALDH1A1MEN1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104714-A1 | PROTEIN EXPRESSION SYSTEMS | NUCLERA LTD (GB) | 2026-05-21 | — | — | WO | claimed |
| US-20260109733-A1 | MULTI-SCALE INTERACTOME PROFILING OF MEMBRANE PROTEINS USING PHOTOCATALYTIC PROXIMITY LABELING | UNIV CALIFORNIA (US) | 2026-04-23 | — | — | US | claimed |
| EP-3849996-B1 | EPITOPE TAGS RECOGNIZED BY SPECIFIC BINDERS | NANOTAG BIOTECHNOLOGIES GMBH (DE) | 2026-04-22 | — | — | EP | claimed |
| EP-4713683-A1 | A METHOD TO HOMOGENIZE THE CONCENTRATION OF BEADS ACROSS MULTIPLE LIQUID VOLUMES | Nuclera Ltd (GB) | 2026-03-25 | — | — | EP | claimed |
| EP-4689663-A1 | PROTEIN EXPRESSION SYSTEMS | Nuclera Ltd (GB) | 2026-02-11 | — | — | EP | claimed |
| EP-4685158-A1 | FIBRILLARY APOLIPOPROTEIN E (APOE) FOR USE IN A METHOD OF TREATMENT AND/OR PREVENTION OF A NEURODEGENERATIVE DISEASE | Technische Universität München (DE) | 2026-01-28 | — | — | EP | claimed |
| US-20260008809-A1 | PROTEIN PURIFICATION | NUCLERA LTD (GB) | 2026-01-08 | — | — | US | claimed |
| US-20250382608-A1 | LINEAR NUCLEIC ACID EXPRESSION CONSTRUCTS | NUCLERA LTD (GB) | 2025-12-18 | — | — | US | claimed |
| EP-4654997-A1 | SARS-COV-2 VACCINE CONSTRUCTS | Rutgers, The State University of New Jersey (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250361326-A1 | METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES | HOFFMANN-LA ROCHE INC. (US) | 2025-11-27 | — | — | US | claimed |
| US-20230167477-A1 | Protein Purification | NUCLERA LTD (GB) | 2023-06-01 | — | — | US | claimed |
| WO-2023079310-A1 | PROTEIN PURIFICATION USING A DIGITAL MICROFLUIDIC DEVICE | NUCLERA NUCLEICS LTD (GB) | 2023-05-11 | — | — | WO | claimed |
| WO-2023079528-A1 | COMPOSITIONS SUITABLE FOR USE IN A METHOD FOR ELICITING CROSS-PROTECTIVE IMMUNITY AGAINST CORONAVIRUSES | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2023-05-11 | — | — | WO | claimed |
| CN-115667281-A | Peptides for preventing or treating synucleinopathies | 国立大学法人东北大学 | 2023-01-31 | — | — | CN | claimed |
| EP-4077372-A1 | NANOBODY EXCHANGE CHROMATOGRAPHY | VIB VZW (BE) | 2022-10-26 | — | — | EP | claimed |
| CN-114595991-A | Energy storage resource supporting capacity online evaluation method and system | 中国电力科学研究院有限公司 | 2022-06-07 | — | — | CN | claimed |
| WO-2022076329-A1 | NANOBODY-OGA FUSIONS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARDCOLLEGE (US) | 2022-04-14 | — | — | WO | claimed |
| US-9295658-B2 | Second generation fatty acid compositions, formulations, and methods of use and synthesis thereof | ATOSSA THERAPEUTICS, INC. | 2016-03-29 | — | — | US | claimed |
| US-20140200267-A1 | Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof | DRACOPHARMA, INC. (US) | 2014-07-17 | — | — | US | claimed |
| US-20110033531-A1 | Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof | DRACOPHARMA, INC. (US) | 2011-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008809-A1 | PROTEIN PURIFICATION | MAX, MYCBP, MRPS22 | CNR1 4346/4885ALDH1A1 4850/4885MEN1 1348/4885 |
| US-20250361326-A1 | METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES | PA2G4, FCGR3B, IGLV6-57 | CNR1 4726/4885ALDH1A1 3833/4885MEN1 2985/4885 |
| US-20250382608-A1 | LINEAR NUCLEIC ACID EXPRESSION CONSTRUCTS | RNGTT, RNMT, MRPS27 | CNR1 4858/4885ALDH1A1 4780/4885MEN1 3214/4885 |
| US-20260109733-A1 | MULTI-SCALE INTERACTOME PROFILING OF MEMBRANE PROTEINS USING PHOTOCATALYTIC PROXIMITY LABELING | TSPO, HLCS, SCO2 | CNR1 1243/4885ALDH1A1 3685/4885MEN1 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.